Literature DB >> 22944724

Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Lucie Amoureux1, Julien Bador1, Eliane Siebor1, Nathalie Taillefumier1, Annlyse Fanton2, Catherine Neuwirth3.   

Abstract

BACKGROUND: Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis (CF) patients recognised as causal agent of inflammation. The prevalence of infection or colonisation is variable among CF centres. We report here the first epidemiological data about A. xylosoxidans in a French CF centre: Dijon, Burgundy.
METHODS: All isolates recovered from the patients affiliated with our centre in 2010 since their first visit were included. Antimicrobial susceptibility was determined by disk diffusion method and E-test. Molecular epidemiology was performed by Pulsed Field Gel Electrophoresis (PFGE) and compared with repetitive sequence-based PCR (rep-PCR, DiversiLab®). We also sequenced the constitutive bla-oxa-114 gene.
RESULTS: Out of 120 patients, 21 (17.5%) had at least one positive culture with A. xylosoxidans since they started to receive routine care in our CF centre (447 isolates). Median age at first positive culture was 16 years (range 3-34 years). Most patients were colonised by their own strain, cross-contamination was very rare. We observed two cases of intra-family spread. DiversiLab® is a useful tool as efficient as PFGE to compare isolates recovered simultaneously from different patients when an outbreak is suspected. However, PFGE remains the reference method for long-term survey of chronically colonised patients. We detected new OXA-114 variants and the new oxacillinase OXA-243 (88% amino acid identity with OXA-114). Acquired resistance to ciprofloxacin, ceftazidime and carbapenems was frequent. In 2010, 7 patients harboured strains resistant to ceftazidime, 6 patients strains with decreased susceptibility to carbapenems (especially meropenem) and 12 patients strains resistant to ciprofloxacin.
CONCLUSIONS: In our centre, the high prevalence of colonisation is not due to cross-contamination. Our main concern is the high rate of antimicrobial resistance.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944724     DOI: 10.1016/j.jcf.2012.08.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  33 in total

1.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

2.  Pseudomonas aeruginosa and Achromobacter sp. clonal selection leads to successive waves of contamination of water in dental care units.

Authors:  Fatima Abdouchakour; Chloé Dupont; Delphine Grau; Fabien Aujoulat; Patricia Mournetas; Hélène Marchandin; Sylvie Parer; Philippe Gibert; Jean Valcarcel; Estelle Jumas-Bilak
Journal:  Appl Environ Microbiol       Date:  2015-08-21       Impact factor: 4.792

3.  Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.

Authors:  Julien Bador; Catherine Neuwirth; Nadège Grangier; Marie Muniz; Leslie Germé; Jérémy Bonnet; Vignesh-Guru Pillay; Catherine Llanes; Claire de Curraize; Lucie Amoureux
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Anne-Laure Michon; Raphaël Chiron; Hélène Marchandin
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

5.  Distribution of allelic variants of the chromosomal gene bla OXA-114-like in Achromobacter xylosoxidans clinical isolates.

Authors:  German Matías Traglia; Marisa Almuzara; Andrea Karina Merkier; Mariana Papalia; Laura Galanternik; Marcela Radice; Carlos Vay; Daniela Centrón; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2013-06-15       Impact factor: 2.188

6.  Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens.

Authors:  German Traglia; Mariana Papalia; Marisa Almuzara; Gabriel Gutkind; Daniela Centrón; Carlos Vay; Marcela Radice; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2014-06-04       Impact factor: 2.188

7.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

Review 8.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones Achromobacter xylosoxidans ST137 and Achromobacter ruhlandii DES from Cystic Fibrosis Patients.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Angélique Chapuis; Véronique Varin; Julien Bador; Nadia Makki; Lise Cremet; Elise Persyn; Emilie Cardot-Martin; Fedoua Echahidi; Charlotte Peeters; Denis Pierard; Peter Vandamme; Alexia Verroken; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2021-08-04       Impact factor: 5.948

10.  Meropenem-Resistant Achromobacter xylosoxidans, Subspecies Denitrificans Bacteremia in a Patient With Stage IV Adenocarcinoma of the Lung.

Authors:  Andre M Agassi; Erin Pollock; Mary M Carter; Robert J Sherertz; Andrew P Mangano
Journal:  Cureus       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.